Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial

K. L. Rice, J. W. Leatherman, P. G. Duane, Linda S Snyder, K. R. Harmon, J. Abel, D. E. Niewoehner

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Study Objective: To determine the efficacy of intravenous aminophylline in the treatment of patients hospitalized for exacerbation of chronic obstructive pulmonary disease. Design: Randomized, double-blind, placebo-controlled trial during the first 72 hours of hospitalization. Patients: Thirty patients admitted from the emergency room or walk-in clinic with the primary diagnosis of an exacerbation of chronic obstructive pulmonary disease. Twenty-eight patients completed the study; 2 patients, 1 receiving placebo and 1 receiving aminophylline, were removed from the study because of respiratory failure requiring mechanical ventilation. Interventions: Patients received either intravenous aminophylline or placebo, in addition to nebulized, inhaled metaproterenol, 0.3 mL of a 5% solution every 6 hours; methylprednisolone, 0.5 mg/kg body weight every 6 hours intravenously; ampicillin, 500 mg orally every 6 hours (tetracycline or trimethoprim-sulfamethoxazole were substituted in penicillin-allergic patients); and supplemental oxygen as needed. Aminophylline infusion rates were adjusted by an unblinded investigator to achieve theophylline levels of 72 to 83 μmol/L. Changes were also made in placebo infusion rates to maintain the double-blind design. Measurements and Main Results: The forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) before and after metaproterenol inhalation were measured twice daily by a blinded investigator, who also administered a verbal dyspnea index with a scale of 1 to 10 and questioned patients regarding possible side effects of treatment (tremor, palpitations, nausea, or vomiting). Arterial blood gas measurements at 72 hours were compared with those obtained on admission. Significant improvements in FEV1 and FVC measured before and after metaproterenol treatment and in dyspnea occurred over time in both treatment groups (p < 0.05 for all measurements). However, there were no significant differences between the placebo and aminophylline groups in any of the spirometric measurements or the dyspnea indices (p > 0.5 in all five analyses). The mean increases (± SE) in P(O2) of 1.9 (± 0.5) kPa with placebo and 1.7 (± 0.7) kPa with aminophylline and the mean decreases in P(CO2) of 0.5 (± 0.4) kPa with placebo and 1.2 (± 0.4) kPa with aminophylline were not significantly different (p > 0.6 for P(O2), p > 0.2 for P(CO2)). Although the difference in the overall incidence of side effects between the two treatment groups, 1 of 13 subjects in the placebo group and 7 of 15 in the aminophylline group was not statistically significant (0.05 < p < 0.10), there was a statistically significant difference in the incidence of gastrointestinal complaints; 6 of 15 and 0 of 13 patients in the aminophylline and placebo groups, respectively (p < 0.05). Conclusions: We were unable to show that the administration of parenteral aminophylline provides significant additional benefits when added to an otherwise standard treatment regimen in patients with chronic obstructive pulmonary disease exacerbations. Although further benefits from aminophylline in this setting might be shown by studies of much larger numbers of patients, these should be weighed against the demonstrated adverse effects.

Original languageEnglish (US)
Pages (from-to)305-309
Number of pages5
JournalAnnals of Internal Medicine
Volume107
Issue number3
StatePublished - 1987
Externally publishedYes

Fingerprint

Aminophylline
Chronic Obstructive Pulmonary Disease
Placebos
Metaproterenol
Vital Capacity
Dyspnea
Therapeutics
Research Personnel
Incidence
Sulfamethoxazole Drug Combination Trimethoprim
Methylprednisolone
Forced Expiratory Volume
Tremor
Ampicillin
Theophylline
Tetracycline
Artificial Respiration
Respiratory Insufficiency
Penicillins
Nausea

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rice, K. L., Leatherman, J. W., Duane, P. G., Snyder, L. S., Harmon, K. R., Abel, J., & Niewoehner, D. E. (1987). Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial. Annals of Internal Medicine, 107(3), 305-309.

Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial. / Rice, K. L.; Leatherman, J. W.; Duane, P. G.; Snyder, Linda S; Harmon, K. R.; Abel, J.; Niewoehner, D. E.

In: Annals of Internal Medicine, Vol. 107, No. 3, 1987, p. 305-309.

Research output: Contribution to journalArticle

Rice, KL, Leatherman, JW, Duane, PG, Snyder, LS, Harmon, KR, Abel, J & Niewoehner, DE 1987, 'Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial', Annals of Internal Medicine, vol. 107, no. 3, pp. 305-309.
Rice, K. L. ; Leatherman, J. W. ; Duane, P. G. ; Snyder, Linda S ; Harmon, K. R. ; Abel, J. ; Niewoehner, D. E. / Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial. In: Annals of Internal Medicine. 1987 ; Vol. 107, No. 3. pp. 305-309.
@article{fcaf0724a1d045aeaaf4a1a88dff55c1,
title = "Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial",
abstract = "Study Objective: To determine the efficacy of intravenous aminophylline in the treatment of patients hospitalized for exacerbation of chronic obstructive pulmonary disease. Design: Randomized, double-blind, placebo-controlled trial during the first 72 hours of hospitalization. Patients: Thirty patients admitted from the emergency room or walk-in clinic with the primary diagnosis of an exacerbation of chronic obstructive pulmonary disease. Twenty-eight patients completed the study; 2 patients, 1 receiving placebo and 1 receiving aminophylline, were removed from the study because of respiratory failure requiring mechanical ventilation. Interventions: Patients received either intravenous aminophylline or placebo, in addition to nebulized, inhaled metaproterenol, 0.3 mL of a 5{\%} solution every 6 hours; methylprednisolone, 0.5 mg/kg body weight every 6 hours intravenously; ampicillin, 500 mg orally every 6 hours (tetracycline or trimethoprim-sulfamethoxazole were substituted in penicillin-allergic patients); and supplemental oxygen as needed. Aminophylline infusion rates were adjusted by an unblinded investigator to achieve theophylline levels of 72 to 83 μmol/L. Changes were also made in placebo infusion rates to maintain the double-blind design. Measurements and Main Results: The forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) before and after metaproterenol inhalation were measured twice daily by a blinded investigator, who also administered a verbal dyspnea index with a scale of 1 to 10 and questioned patients regarding possible side effects of treatment (tremor, palpitations, nausea, or vomiting). Arterial blood gas measurements at 72 hours were compared with those obtained on admission. Significant improvements in FEV1 and FVC measured before and after metaproterenol treatment and in dyspnea occurred over time in both treatment groups (p < 0.05 for all measurements). However, there were no significant differences between the placebo and aminophylline groups in any of the spirometric measurements or the dyspnea indices (p > 0.5 in all five analyses). The mean increases (± SE) in P(O2) of 1.9 (± 0.5) kPa with placebo and 1.7 (± 0.7) kPa with aminophylline and the mean decreases in P(CO2) of 0.5 (± 0.4) kPa with placebo and 1.2 (± 0.4) kPa with aminophylline were not significantly different (p > 0.6 for P(O2), p > 0.2 for P(CO2)). Although the difference in the overall incidence of side effects between the two treatment groups, 1 of 13 subjects in the placebo group and 7 of 15 in the aminophylline group was not statistically significant (0.05 < p < 0.10), there was a statistically significant difference in the incidence of gastrointestinal complaints; 6 of 15 and 0 of 13 patients in the aminophylline and placebo groups, respectively (p < 0.05). Conclusions: We were unable to show that the administration of parenteral aminophylline provides significant additional benefits when added to an otherwise standard treatment regimen in patients with chronic obstructive pulmonary disease exacerbations. Although further benefits from aminophylline in this setting might be shown by studies of much larger numbers of patients, these should be weighed against the demonstrated adverse effects.",
author = "Rice, {K. L.} and Leatherman, {J. W.} and Duane, {P. G.} and Snyder, {Linda S} and Harmon, {K. R.} and J. Abel and Niewoehner, {D. E.}",
year = "1987",
language = "English (US)",
volume = "107",
pages = "305--309",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial

AU - Rice, K. L.

AU - Leatherman, J. W.

AU - Duane, P. G.

AU - Snyder, Linda S

AU - Harmon, K. R.

AU - Abel, J.

AU - Niewoehner, D. E.

PY - 1987

Y1 - 1987

N2 - Study Objective: To determine the efficacy of intravenous aminophylline in the treatment of patients hospitalized for exacerbation of chronic obstructive pulmonary disease. Design: Randomized, double-blind, placebo-controlled trial during the first 72 hours of hospitalization. Patients: Thirty patients admitted from the emergency room or walk-in clinic with the primary diagnosis of an exacerbation of chronic obstructive pulmonary disease. Twenty-eight patients completed the study; 2 patients, 1 receiving placebo and 1 receiving aminophylline, were removed from the study because of respiratory failure requiring mechanical ventilation. Interventions: Patients received either intravenous aminophylline or placebo, in addition to nebulized, inhaled metaproterenol, 0.3 mL of a 5% solution every 6 hours; methylprednisolone, 0.5 mg/kg body weight every 6 hours intravenously; ampicillin, 500 mg orally every 6 hours (tetracycline or trimethoprim-sulfamethoxazole were substituted in penicillin-allergic patients); and supplemental oxygen as needed. Aminophylline infusion rates were adjusted by an unblinded investigator to achieve theophylline levels of 72 to 83 μmol/L. Changes were also made in placebo infusion rates to maintain the double-blind design. Measurements and Main Results: The forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) before and after metaproterenol inhalation were measured twice daily by a blinded investigator, who also administered a verbal dyspnea index with a scale of 1 to 10 and questioned patients regarding possible side effects of treatment (tremor, palpitations, nausea, or vomiting). Arterial blood gas measurements at 72 hours were compared with those obtained on admission. Significant improvements in FEV1 and FVC measured before and after metaproterenol treatment and in dyspnea occurred over time in both treatment groups (p < 0.05 for all measurements). However, there were no significant differences between the placebo and aminophylline groups in any of the spirometric measurements or the dyspnea indices (p > 0.5 in all five analyses). The mean increases (± SE) in P(O2) of 1.9 (± 0.5) kPa with placebo and 1.7 (± 0.7) kPa with aminophylline and the mean decreases in P(CO2) of 0.5 (± 0.4) kPa with placebo and 1.2 (± 0.4) kPa with aminophylline were not significantly different (p > 0.6 for P(O2), p > 0.2 for P(CO2)). Although the difference in the overall incidence of side effects between the two treatment groups, 1 of 13 subjects in the placebo group and 7 of 15 in the aminophylline group was not statistically significant (0.05 < p < 0.10), there was a statistically significant difference in the incidence of gastrointestinal complaints; 6 of 15 and 0 of 13 patients in the aminophylline and placebo groups, respectively (p < 0.05). Conclusions: We were unable to show that the administration of parenteral aminophylline provides significant additional benefits when added to an otherwise standard treatment regimen in patients with chronic obstructive pulmonary disease exacerbations. Although further benefits from aminophylline in this setting might be shown by studies of much larger numbers of patients, these should be weighed against the demonstrated adverse effects.

AB - Study Objective: To determine the efficacy of intravenous aminophylline in the treatment of patients hospitalized for exacerbation of chronic obstructive pulmonary disease. Design: Randomized, double-blind, placebo-controlled trial during the first 72 hours of hospitalization. Patients: Thirty patients admitted from the emergency room or walk-in clinic with the primary diagnosis of an exacerbation of chronic obstructive pulmonary disease. Twenty-eight patients completed the study; 2 patients, 1 receiving placebo and 1 receiving aminophylline, were removed from the study because of respiratory failure requiring mechanical ventilation. Interventions: Patients received either intravenous aminophylline or placebo, in addition to nebulized, inhaled metaproterenol, 0.3 mL of a 5% solution every 6 hours; methylprednisolone, 0.5 mg/kg body weight every 6 hours intravenously; ampicillin, 500 mg orally every 6 hours (tetracycline or trimethoprim-sulfamethoxazole were substituted in penicillin-allergic patients); and supplemental oxygen as needed. Aminophylline infusion rates were adjusted by an unblinded investigator to achieve theophylline levels of 72 to 83 μmol/L. Changes were also made in placebo infusion rates to maintain the double-blind design. Measurements and Main Results: The forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) before and after metaproterenol inhalation were measured twice daily by a blinded investigator, who also administered a verbal dyspnea index with a scale of 1 to 10 and questioned patients regarding possible side effects of treatment (tremor, palpitations, nausea, or vomiting). Arterial blood gas measurements at 72 hours were compared with those obtained on admission. Significant improvements in FEV1 and FVC measured before and after metaproterenol treatment and in dyspnea occurred over time in both treatment groups (p < 0.05 for all measurements). However, there were no significant differences between the placebo and aminophylline groups in any of the spirometric measurements or the dyspnea indices (p > 0.5 in all five analyses). The mean increases (± SE) in P(O2) of 1.9 (± 0.5) kPa with placebo and 1.7 (± 0.7) kPa with aminophylline and the mean decreases in P(CO2) of 0.5 (± 0.4) kPa with placebo and 1.2 (± 0.4) kPa with aminophylline were not significantly different (p > 0.6 for P(O2), p > 0.2 for P(CO2)). Although the difference in the overall incidence of side effects between the two treatment groups, 1 of 13 subjects in the placebo group and 7 of 15 in the aminophylline group was not statistically significant (0.05 < p < 0.10), there was a statistically significant difference in the incidence of gastrointestinal complaints; 6 of 15 and 0 of 13 patients in the aminophylline and placebo groups, respectively (p < 0.05). Conclusions: We were unable to show that the administration of parenteral aminophylline provides significant additional benefits when added to an otherwise standard treatment regimen in patients with chronic obstructive pulmonary disease exacerbations. Although further benefits from aminophylline in this setting might be shown by studies of much larger numbers of patients, these should be weighed against the demonstrated adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=0023263423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023263423&partnerID=8YFLogxK

M3 - Article

C2 - 3619219

AN - SCOPUS:0023263423

VL - 107

SP - 305

EP - 309

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -